MARKET

STIM

STIM

Neuronetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.830
+0.020
+0.00%
Closed 16:00 06/01 EDT
OPEN
1.850
PREV CLOSE
1.830
HIGH
1.960
LOW
1.830
VOLUME
164.55K
TURNOVER
--
52 WEEK HIGH
13.31
52 WEEK LOW
1.250
MARKET CAP
34.27M
P/E (TTM)
-0.9955
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average STIM stock price target is 6.25 with a high estimate of 9.00 and a low estimate of 4.000.

EPS

STIM News

More
Neuronetics, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
GlobeNewswire · 05/12 22:21
Neuronetics, Inc. (STIM) Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 18:40
Neuronetics Recognizes Critical Health Professionals During Mental Health Awareness Month
Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is celebrating the professionals delivering cri
GlobeNewswire · 05/07 12:00
Neuronetics, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/05 14:16
Neuronetics (STIM) Reports Q1 Loss, Misses Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of -54.55% and -3.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 11:30
Neuronetics Reports First Quarter 2020 Financial and Operating Results
GlobeNewswire · 05/05 11:00
Neuronetics Q1 EPS $(0.680) Misses $(0.500) Estimate, Sales $11.480M Miss $13.010M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.680) per share which missed the analyst consensus estimate of $(0.500) by 36 percent. This is a 61.9 percent decrease over losses of $(0.420) per share from the
Benzinga · 05/05 10:12
Neuronetics to Report First Quarter 2020 Financial and Operating Results and Host Conference Call
GlobeNewswire · 04/21 13:00

Industry

Advanced Medical Equipment & Technology
+0.58%
Healthcare Equipment & Supplies
+0.10%

Hot Stocks

Symbol
Price
%Change

About STIM

Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.
More

Webull offers kinds of Neuronetics Inc stock information, including NASDAQ:STIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STIM stock news, and many more online research tools to help you make informed decisions.